Artículos del autor

solaci

Day 2

Bivalirudin superior than heparin beyond the use or not of Glycoprotein inhibitors

Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though  this benefit...
solaci -
Day 1

ORBIT II: atherectomy for heavily calcified lesions

The aim of this study was to evaluate the safety and efficacy of coronary orbital atherectomy system...
solaci -
Day 2

Safety and efficacy of Cardiobrand device for percutaneous mitral annuloplasty

The Cadiobrand device is implanted through a transseptal approach and makes a reduction in the mitral annulus...
solaci -
Day 2

SALUS: New percutaneous valve with promising results regarding aortic regurgitation post implant.

Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim...
solaci -
Day 2

DESSOLVE II: 2-year results show the superiority of the sirolimus eluting stent with fast bio -absorbable polymer.

The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio...
solaci -
Day 2

ACCOAST: pretreatment with prasugrel in non-ST elevation acute coronary syndrome (NSTE-ACS) offers no benefit and increased bleeding

P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This...
solaci -
Day 2

SORT-OUT V: Similar results of biolimus eluting stent with biodegradable polymer versus sirolimus eluting stent with permanent polymer.

The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent...
solaci -
Day 2

BLESS: assessment of platelet reactivity in patients undergoing angioplasty receiving prasugrel.

The aim of this study was to evaluate the modification in residual platelet reactivity by adjusting the...
solaci -